Live Breaking News & Updates on கேப்ரியல் அறிவியல்

Stay updated with breaking news from கேப்ரியல் அறிவியல். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2021 Financial Results


Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2021 Financial Results
 | 

Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care,
eye, oral and nasal care and dermatological conditions today announced financial results for fiscal year 2021 and the fourth quarter ended March 31, 2021.
“For the past 18 months we have been restructuring the Company to cut losses while positioning it for growth,” said Amy Trombly, CEO. “Last year we consolidated all manufacturing at our factory in
Mexico (June), and ended our contract with Invekra that required us to sell product with low margin (October). This year, we entered into a partnership agreement with EMC Pharma, LLC for the sale ....

United States , New Zealand , Hong Kong , Testsieger Finanztest , Gabriel Science , Te Arai Biofarma Ltd , Sonoma Pharmaceuticals Inc , Cpharmaceuticals Aktie , Exchange Commission , Sonoma Pharmaceuticals , Vetsynova Co , Nasocyn Nasal Care , Oracyn Oral , Middle East , Quarter Ended March , Latin America , Year Ended March , Private Securities Litigation Reform , Ended March , ஒன்றுபட்டது மாநிலங்களில் , புதியது ஜீலாந்து , ஹாங் காங் , கேப்ரியல் அறிவியல் , தே அராய் உயிர் பார்மா லிமிடெட் , சோணோமா மருந்துகள் இன்க் , பரிமாற்றம் தரகு ,

Sonoma Pharmaceuticals Announces Partnership with Gabriel Science, LLC For Dental Markets


Sonoma Pharmaceuticals Announces Partnership with Gabriel Science, LLC For Dental Markets
Sonoma Pharmaceuticals Announces Partnership with Gabriel Science, LLC For Dental Markets
Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal care, disinfectant use and dermatological conditions, today announced that it has entered into a non-exclusive distribution agreement with Gabriel Science, LLC for the sale of Microcyn Technology products into the dental market and has accepted its first order.
Endocyn, a Microcyn Technology product manufactured by Sonoma, is a biocompatible root canal irrigant that does not stain teeth or restorations. In a study conducted by the Departments of Endodontics and Cell Biology and Anatomy at Louisiana State University School of Dentistry published in the Journal of Endodontics, Regen ....

United States , Mark Fontenot , Amy Trombly , Exchange Commission , Sonoma Pharmaceuticals Inc , Gabriel Science , Louisiana State University School Of Dentistry , Sonoma Pharmaceuticals , Microcyn Technology , Cell Biology , Louisiana State University School , Regenerative Endodontics , Private Securities Litigation Reform Act , ஒன்றுபட்டது மாநிலங்களில் , குறி ஃபாந்‌டெநட் , பரிமாற்றம் தரகு , சோணோமா மருந்துகள் இன்க் , கேப்ரியல் அறிவியல் , லூசியானா நிலை பல்கலைக்கழகம் பள்ளி ஆஃப் பல் மருத்துவம் , சோணோமா மருந்துகள் , செல் உயிரியல் , லூசியானா நிலை பல்கலைக்கழகம் பள்ளி , மீளுருவாக்கம் எண்டோடோன்டிக்ஸ் , ப்ரைவேட் பத்திரங்கள் வழக்கு சீர்திருத்தம் நாடகம் ,